RESEARCH
Circulating Tumor DNA Shows Promise for Guiding Adjuvant Therapy After Curative SurgeryA review examines how circulating tumor DNA (ctDNA) offers a dynamic readout of molecular residual disease in the postoperative period, potentially guiding adjuvant treatment decision-making in stage II (15-20% recurrence) and stage III (30-40% recurrence) CRC. (Biomedicines)